PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34740818-3	2021	In a target identification assay of anti-cancer compound using a modified DrugTargetSeqR strategy, mutation of TOP3B was detected in cancer cells acquired resistance to cinobufagin (CBG), a key compound of Huachansu that has been approved for cancer therapy in China.	cinobufagin	169-180	DNA topoisomerase III beta	Homo sapiens	111-116	
34740818-3	2021	In a target identification assay of anti-cancer compound using a modified DrugTargetSeqR strategy, mutation of TOP3B was detected in cancer cells acquired resistance to cinobufagin (CBG), a key compound of Huachansu that has been approved for cancer therapy in China.	cinobufagin	182-185	DNA topoisomerase III beta	Homo sapiens	111-116	
34740818-6	2021	We also demonstrated that CBG induced formation of stress granule, RNA-loop and asymmetric DNA damages in cancer cells, and all these phenotypes were significantly attenuated in TOP3B knockout cells.	cinobufagin	26-29	DNA topoisomerase III beta	Homo sapiens	178-183	
34740818-7	2021	Of note, examination of a panel of cancer cell lines revealed associations among cell growth inhibition and induction of DNA damage as well as TOP3B depletion upon CBG treatment.	cinobufagin	164-167	DNA topoisomerase III beta	Homo sapiens	143-148